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Specific Binding of Cardiac Glycoside Drugs and Endogenous Digitalis-like Substances to
Particulate Membrane Fractions from Human Placenta
Anna Pad, Franca CoccI, Francesca Piras, Glullano ClarImboll, and Aldo Clerico
We studied the characteristicsof bindingof cardiac gylco-
sides to particulate membrane fractions from human pla-
centa, to demonstrate that placental tissue is a suitable
source of receptors for digitalis drugs. Moreover, we per-
formed preliminary experiments with 1251-Iabeled igoxin and
placental particulates to develop a radioreceptor assay for
measurement of endogenous substances with activity similar
to cardiacglycoside drugs (EDLS). Placental membrane
fractions were incubated with [3H]ouabain (10 nmol/L) or
1251-labeleddigoxin (50 pmol/L). With both ligands, binding
followeda pseudo-first-orderreactionkineticsand was sat-
urable. Scatchard analysis revealed a single class of sites
[forouabain, K0 = 20.2 ± 5.8 nmol/L (mean ± SEM), Bmw,
= 3.1 ± 0.9 nmol per gram of protein; for digoxin, K, = 29.7
± 1.9 nmol/L, Bm = 24.3 ± 1.1 nmol per gram of protein].
As expected, digoxin was less potent than ouabain in dis-
placing both tracers from digitalisdrugs receptors;proges-
terone, cortisone, digitoxose,furosemide, bumetanide,and
propranolol had no or little effect. Specific 1251-Iabeled
digoxin binding was competitivelyinhibitedby plasma and
(or) urine extracts from newborns, adults, pregnant women,
and patients with renal insufficiency. Inhibitionof bindingand
volume of plasma and urine assayed were linearly related.
These findings support the hypothesisthat cardiac glyco-
sides and EDLS can interact with the human placenta and
suggest placental tissue to be a suitable source of receptors
for cardiac glycosides.
The presence of an endogenous substance (or some en-
dogenous factors) with digitalis-like immunoreactivity in
biological fluids of humans and experimental animals was
well confirmed (for review see references 1 and 2). Digoxin-
like immunoreactivity was detectable in plasma (or serum)
of normal adult subjects, whereas concentrations were
significantly higher in pregnant women, newborns, pa-
tients with renal impairment, and in some patients with
arterial hypertension (1,2). Some authors have postulated
that an endogenous cardiac-glycoside-like factor might
play a role in regulating fluid volume and in the pathogen-
esis of some forms of essential hypertension (2, 3) and of
eclampsia in pregnancy (2,4-6). It was suggested (2) that
digoxin-like immunoreactive substance(s) could also in-
hibit the membrane Na/K pump by binding to the
specific cardiac glycoside receptor (Na/K-dependent
ATPase; EC 3.6.1.37). Therefore, these endogenous factors
could have both the immunoreactive and biological proper-
ties of cardiac glycoside drugs.
At present, there is no agreement on the best proce-
dure(s) for detecting and measuring this (these) endoge-
nous substance(s) (2, 7). Use of antiserum to digoxin in
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immunological methods for assay of digoxin-like immuno-
reactivity can give some erroneous findings and difficulties
in interpretation of results (2, 7). Specific and nonspecific
interferences probably are both present in all digoxin
immunoassays, and the ratio between these two forms of
interferences probably varies greatly with different immu-
nological methods, and also in the same system when
different lots of antiserum are used or the assay procedures
(incubation time or temperature) are changed (2, 7).
The non-immunological procedures (radioreceptor assay,
measurement of the inhibition of ion transport across the
membrane, or of Na/K-ATPase activity) are considered
more specific for the measurement of digitalis-like sub-
stances, but are generally cumbersome, time consuming,
and less sensitive than immunological methods (2, 7).
Recently, a radioreceptor assay has been described for
measurement of digoxin in which [3H]digoxin is used as
tracer and NaVK-ATPase from autopsied human heart
as receptors (8). However, autopsy material is not easily
available, and membranes prepared from autopsy tissues
may be affected by a general loss of receptors and unpre-
dictable changes of binding properties (9).
Whitsett and Wallick (10) reported the presence of spe-
cific receptors for [3Hlouabain in human placenta. There-
fore, we studied the binding characteristics of cardiac
glycosides to membrane preparations from human placenta
to demonstrate that placental tissue may be a suitable
source of digitalis drugs receptors. Moreover, lmIlabeled
tracers generally improve the practicability and the sensi-
tivity of RIAs and radioreceptor assays, so we performed
preliminary experiments with ‘251-labeled digoxin and
placental particulates, to develop a radioreceptor assay for
measurement of endogenous substances with activity sim-
ilar to that of cardiac glycoside drugs.
Materials and Methods
Preparation of placental membranes. Particulate mem-
brane fractions from human placenta were prepared as
described by Schocken et al. (11). Term placentas, obtained
with consent immediately after delivery, were trimmed
free of adherent membranes, minced, and homogenized
with a Kinematica GmbH Polytron PT 10-35 in 2.5 vol-
umes of ice-cold homogenization buffer (per liter, 250 mmol
of sucrose, 1 mmol of MgC12, and 5 mmol of Tris hydrochlo-
ride, pH 7.4, at 4#{176}C)by means of three consecutive 10-s
bursts at maximum speed. The homogenates were filtered
through two layers of cheesecloth and subjected to differ-
ential centrifugation at 4 #{176}C.After centrifugation for 10
mm at 2000 x g, the supernates were centrifuged at 39000
x g for 10 mm. The resulting pellets were resuspended by
gentle homogenization at 4#{176}Cin 50 mmol/L Tris hydro-
chloride buffer, pH 7.4, washed, and recentrifuged twice
under the same conditions. The final pellets were resus-
pended in the same buffer at a protein concentration of
8-12 gIL and kept frozen at -70 #{176}Cuntil used (for as long
as two months). Protein was quantified with the BCA
Protein Assay Reagent (Pierce Chemical Co., Rockford, IL)
with bovine serum albumin (Cohn Fraction V; Sigma
Chemical Co., St. Louis, MO) as the standard.
Receptor binding assay. The technique for measuring
[3H}ouabain binding was a modification of that described
by Lichtstein and Samuelov (12). The incubation mixture
consisted of 200 uL of placental membranes (50 zg of
protein), 50 L of [3H]ouabain (10 nmoIJL; NEN Du Pont,
Boston, MA; specific radioactivity 25 kCilmol), 10 pL of 100
mmoIJL ATP (vanadium-free, Sigma Chemical Co.), and 50
iL of competing ligands at various concentrations in a total
volume of 500 L of incubation buffer (per liter: 0.5 mmol of
EDTA, 80 mmol of NaCl, 4 mmol of Mg504, and 50 mmol
of Ths hydrochloride, pH 7.4, at 37#{176}C).[3H]Ouabain and
all other uganda were freshly prepared in incubation
buffer. We terminated the reaction by adding 4 mL of 50
mmol/L Tris hydrochloride buffer, pH 7.4, at 37 #{176}C,followed
by rapid filtration through GF/C glass-fiber ifiters (What-
man Inc., Clifton, NJ). Each filter was washed three times
with an additional 4 mL of the same buffer, and the
radioactivity bound to the filter was counted by standard
liquid-scintillant technique at about 45% efficiency. Spe-
cific binding of [3Hljouabain was defined as the difference
between radioactivity bound in the absence or presence
during incubation of ouabain, 0.1 mmol/L. The filter blank
accounted for most of the usual nonspecific binding.
For lThIlabeled digoxin binding, 200 jL of placental
membranes (150 g of protein) and 50 pL of ‘I-labeled
digoxin (0.5 nmol/L; NEN Dii Pont; specific radioactivity
2200 kCilmol) were incubated in polypropylene tubes at
37 #{176}C,with or without 100 L of digoxin solutions (from 10
nmol/L to 10 mol/L) or sample extracts in a total volume
of 500 pL of incubation buffer (per liter: 5 mmol of MgCl2,
5 mmol of Na2HPO4, and 50 mmol of Tris hydrochloride,
pH 7.4, at 37 #{176}C).After incubation, 400 pL of the incuba-
tion mixture was transferred to pre-chilled microtubes and
promptly centrifuged in a Beckman Microfuge B for 2.5
mm at 4#{176}C.Membrane pellets were washed with 400 L of
50 mmolJL Tris hydrochloride buffer, pH 7.4, at 4#{176}Cand
counted in a gamma spectrometer at about 75% efficiency.
We chose centrifugation because a large amount of 1251..
labeled digoxin was nonspecifically bound to glass-fiber
ifiters, thus obscuring specific receptor binding of the hg-
and. A 10 mmol/L stock solution of digoxin was prepared in
dimethyl sulfoxide, which did not affect the maximal spe-
cific binding of ‘251-labeled digoxin to the membranes.
Subsequent dilutions were prepared in incubation buffer.
Specific binding of 1251-labeled digoxin was defined as the
difference between radioactivity bound in the absence or
presence, during incubation, of digoxin, 10 moI/L.
Each binding assay was performed in duplicate and
repeated at least three times. Binding data were expressed
as mean ± SEM. The values measured by the radioreceptor
assay were expressed as digoxin equivalents (nmol per liter
of serum or urine). We used a Macintosh SE personal
computer to analyze receptor radioligand curves and re-
sults. The precision profile of the radioreceptor assay was
calculated by previously described computer programs (13,
14).
Samples. Plasma pools from 44 normal subjects, from six
uremic patients, and from more than 50 pregnant women
in the first, second, and third trimesters of pregnancy; one
pooled specimen of serum from some newborns (cord blood);
and two urine pools from some newborns (first or second
postnatal day) and from normal adult subjects were pre-
pared and stored at -20 #{176}Cuntil assayed with the radiore-
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Before the analysis, each plasma (serum) or urine sample
was extracted on fresh SepPak C18 cartridges (Waters
Associates) as previously described (15). A 2-mL sample
was applied to each cartridge that had been previously
activated with 4 mL of methanol followed by 20 mL of
distilled water. After we washed the resin with 40 mL of
distilled water, each cartridge was eluted with 4 mL of
methanol. The extracts were evaporated under reduced
pressure, the dry residues were redissolved in 250 zL of
incubation buffer, and 100 .L of this solution were then
used in the radioreceptor assay.
Extraction of urine or plasma (serum) samples with
SepPak C18 cartridges avoided interferences from ions
(such as K) (15), proteins, or fatty acids. More than 99.5%
of the albumin or total proteins in the sera, and more than
99% of the free fatty acids were eliminated by the washings
of the resin. Moreover, even though steroid hormones are
surely present in the extracts, we found that progesterone
or cortisone, at least, did not significantly inhibit I-
labeled digoxin binding (see Results, Figure 5a). The ex-
traction procedure, moreover, allowed an eightfold concen-
tration of samples.
Results
[3H]Ouabain binding to placental membranes. The bind-
ing of [3H]ouabain to particulate membrane fractions from
human placenta was time-, protein-, and ligand-concentra-
tion dependent. At 10 nmol of [3Hlouabain per liter and 0.1
mg of protein per milliliter, respectively, specific binding
reached a steady-state of 1.53% within 2 h and remained
constant until 5 h. During this time, nonspecific binding
was less than 2% of the total binding.
The binding of [3Hlouabain to placental membranes was
a saturable process (Figure la). Scatchard analysis (16) of
the specific binding data, as shown in Figure lb, revealed a
single class of binding sites with a KD value of 20.2 ± 5.8
nmol/L and a binding capacity of 3.1 ± 0.9 nmol per gram
of protein. Binding of [3H]ouabain was competitively inhib-
ited by unlabeled ouabain and digoxin, with 50% inhibition
at concentrations of about 10 nmol/L and 30 nmol/L,
respectively (Figure 2). In contrast, furosemide, (±)-pro-
pranolol, and (-)-norepinephrine had no effect in concen-
trations up to 10 mmol/L (Figure 2). The dissociation
constant for the interaction of digoxin with E3H]ouabain
binding sites, as calculated by the equation of Cheng and
Prusoff (17), was 22.3 ± 3.5 nmolfL.
Specific ouabain binding to human placental membranes
was inhibited by a serum extract of umbilical cord blood
(Figure 3). Binding inhibition, up to a concentration of 1
nmol of ouabain per liter, was about 45% (Figure 3). A
change in affinity, rather than in the receptor number,
seems to account for the observed change in [3Hlouabain
binding. In contrast, plasma extracts from blood donors had
no significant effect on the specific binding of [3Hjouabain
to human placental membranes (data not shown).
1251-labekd digoxin binding to placental membranes. The
time course of total, specific, and nonspecific binding of
‘251-labeled digoxin (50 pmoIJL) to human placental partic-
ulates (300 .ig/mL) at 37#{176}Cand pH 7.4 is shown in Figure
4. Specific binding reached a plateau (26.5% ± 2.6%) within
4 h and remained constant for 2 h more. Nonspecific
binding averaged 4.6% ± 1.0%. The time required to obtain
steady-state decreased with increasing 1251-labeled digoxin
or protein concentration.
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Fig. 1. a. Saturation curve of rH)ouabain to human placental
membranes:#{149},specific binding; 0, nonspecificbinding
The data representthe mean of fourexpenmentsconducted In duplicate
b. Scatchardplotof the specific binding data from Fig. 1a
B/F = bound[H]ouabain/free rH)ouabaln
Specific binding increased linearly (r = 0.99, n = 6) with
increasing protein concentration up to a value of nearly 400
mg/L and became saturated at protein concentrations ex-
ceeding 700 mgfL (data not shown). An incubation time of
5 h and a protein concentration of 300 mgIL were therefore
routinely used.
To evaluate binding specificity, we studied the ability of
several unlabeled higands to inhibit the binding of ‘WI-
labeled digoxin to placental particulates (Figure 5a). 1251..
Labeled digoxin binding was inhibited in a dose-dependent
Time (mm)
Fig. 4. Time course of total (#{149}),specific (0), and nonspecific(#{149})
1tmI-Iabeled digoxinbinding(50pmol/L) to human placentalmem-
branes(300 gIL) at 37#{176}C,pH 7.4
manner by ouabain, digoxin, and digoxigenin, one of the
cardioactive metabolites of digoxin. As expected, ouabain
was more effective than digoxin in inhibiting binding with
EC50 values (molar concentration for 50% inhibition) of
about 7 nmoliL and 45 nmol/L, respectively. The inhibition
constant for ‘I-labeled digoxin binding to placental mem-
branes by ouabain was 7.2 ± 1.0 nmol/L. Digoxigernn,
which was reported to have a lower cardioactivity than
digoxin (18), was unexpectedly found to have the same
potency in displacing ‘25I-labeled digoxin from its binding
sites. However, the shape of the displacement curve for the
two substances was quite different: the curve for digoxige-
nm was fiat and, after transformation into a “pseudo
Scatchard plot” (19)-i.e., by plotting percent inhibition of
binding vs percent inhibition divided by digoxigemn con-
centration-curvilinear plots were obtained. In contrast,
when the specific digoxin binding data were analyzed
according to Scatchard (16), as presented in Figure 5b, a
linear plot was obtained, suggesting one class of binding
sites with a KD value of 29.7 ± 1.9 nmol/L and a of
24.3 ± 1.1 nmol per grain of protein.
‘251..Labeled digoxin bound to human placental particu-
lates was not displaced by digitoxose (one of the cardio-
inactive metabolites of digoxin) or by steroids such as
cortisone and progesterone (Figure 5a). Bumetanide (the
specific inhibitor of the cotransport system), furosemide,
and (±)-propranolol inhibited binding only at concentra-
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FIg.5. a. Inhibitionof specific1#{176}l-Iabeleddigoxinbindingto human
placentalmembranesby (0) ouabain, (0) digoxln, (#{149})digoxigenin,
(0) dlgitoxose, (+) progesterone, () cortisone,(U) furosemide, (X)
bumetanide,and (A)(±)-propranolol; b. Scatchardplot of specific
dlgoxlnbindingdata
B/F = bound1l-Iabeled digoxin/free ‘25l-Iabeleddigoxin.Mean ± SEM
tions exceeding 100 p.mol/L (Figure 5a).
Radioreceptor assay using ‘251-labeled digoxin. A typical
standard curve of the radioreceptor assay for the measure-
ment of endogenous digitalis-like substances, in which
‘251.labeled digoxin (50 pmol/L) is used as a tracer and with
particulate membrane fractions from human placenta (300
mg/L) as receptors, is shown in Figure 6. The standard-
curve concentrations ranged from 0 to 1 umol of digoxin per
Digoxin added, nmol/L
Fig. 6. Typical standard curve and precisionprofile (insel) of the
radioreceptor assay
liter. The mean sensitivity (n = 7) of the assay was 5.7 ±
0.9 nmol/L.
Linear relationships with correlation coefficients >0.98
were found between the volumes assayed and the digoxin
equivalents measured by the radioreceptor assay in dif-
ferent pooled specimens of plasma (serum) or urine from
newborns, adult normal subjects, pregnant women, and
uremic patients (data not shown).
Newborns, pregnant women, and uremic patients
showed higher values for circulating digitalis-like sub-
stances than did normal subjects; moreover, higher values
were found for urine of newborns and adult subjects com-
pared with those for plasma (Table 1).
Discussion
Our findings confirm that specific receptors for cardiac
glycoside drugs are present in human placenta and indicate
that this tissue may be a readily available source of
NafK-ATPase. In fact, the putative receptor showed
high affinity and saturable binding to [3H]ouabain and
1251-labeled digoxin. The affinity of placental Na’/K-
ATPase for digitalis drugs was similar to that shown by the
enzyme isolated from other tissues [e.g., dog kidney, por-
cine heart, human heart (8), human erythrocytes (20)1, and
the maximum number of binding sites was high. As ex-
pected, digoxin was less potent than ouabain in displacing
tracer from digitalis drugs receptors, whereas digitoxose,
progesterone, cortisone, furosemide, buinetanide, and (±)-
propranolol had no or little effect.
Multiple sites with high and low affinity for cardiac
glycosides have been reported in rat cardiac ventricle (21)
and cultured chick heart cells (22), with [3H]ouabain used
as a ligand. The presence of multiple forms of binding sites
with different affinity to digitalis drugs may affect the
sensitivity and specificity of a radioreceptor assay. How-
ever, in the present study both [3Hlouabain and ‘I-
labeled digoxin shared only one class of binding sites for
cardiac glycosides in the human placenta, thus confirming
[3H]ouabain binding data previously reported by Whitsett
and Wallick (10), and indicating that human placenta is a
suitable tissue for radioreceptor assay of digitalis drugs.
The 1251-labeled digoxin was found to label digitalis
drugs receptors of the human placenta with an affinity
similar to that shown by [8H]ouabain, but its use enhanced
practicability and sensitivity of the radioreceptor assay of
digoxin-like immunoreactive substances.
A linear relationship was found between the volumes
assayed and the digoxin equivalents measured by the
Table 1. Digitalis-like Substances Measured by
Radioreceptor Assay in Pooled Specimens of Urine
and (or) Plasma from Various Groups of Subjects
Digoxin equIvalents,
Sample nmol/L
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‘251-labeled digoxin radioreceptor assay in different plasma
(serum) or urine pools of newborns, adult normal subjects,
pregnant women, and uremic patients. As expected (1,2),
pooled specimens of plasma (serum) from newborns, preg-
nant women, and uremic patients showed higher values for
digitalis-like substances in the circulation than did a
plasma pool from normal subjects. Moreover, higher values
were found for urine of newborns and adult subjects as
compared with concentrations inthe circulation.
The presence of high-affinity digitalis drugs receptors in
human placenta and the high values for endogenous digi-
talis-like substances in the circulation of mothers and
newborns indicate that these endogenous factors may have
an important role in the regulation of electrolyte and fluid
balance in the feto-placental unit and in the pathogenesis
of hypertension and eclampsia in pregnancy, as also sug-
gested by other authors (4-6).
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